Home / Pharma News

Pharma News

Endo to buy specialty generic drugmaker Boca Pharmacal

Specialty pharmaceutical maker Endo Health Solutions (Endo) announced on 28 August 2013 that its generics subsidiary, Qualitest, has agreed to buy specialty generic drugmaker Boca Pharmacal (Boca) for US$225 million in cash.

Actavis and Bioton form joint venture for insulin

Icelandic generics manufacturer Actavis announced on 30 January 2012 that it had formed a joint venture company with Polish biotechnology company Bioton for the development and registration of insulin products, including analogue insulins.

Philippines urged to import drugs from Bangladesh

The Prime Minister of Bangladesh, Ms Sheikh Hasina, on 5 May 2013 urged the Philippines to import pharmaceutical products from Bangladesh, particularly for the countries governmental hospitals and clinics, due to the significant cost-savings to be made.

Generics manufacturers increase investment in injectables

Generic drugmaker Zydus Cadila, the fifth largest pharmaceutical company in India, is set to invest about US$15.8 million in building an FDA-approved injectables-manufacturing plant. The news in August 2013 came just as Aurobindo Pharma announced plans to spin-off its injectables business to strengthen that side of its operations further.

Fresenius Kabi sets up generics joint venture in Indonesia

Fresenius Kabi, the generics unit of healthcare giant Fresenius, announced on 19 August 2013 that it had set up a joint venture with Indonesia-based PT Soho Global Health, acquiring a 51% share in its subsidiary PT Ethica Industri Farmasi.

Perrigo expands global ambitions with Elan buy

US-based generics maker Perrigo Company (Perrigo) announced on 29 July 2013 that it would acquire Irish biotechnology company Elan Corporation (Elan) for US$8.6 billion.

Pfizer prepares to split off generics business

Pfizer, the world’s largest research-based pharmaceutical company, has announced plans to split off its generics drug business into a separate commercial operation. News of the plans came as the company reported its second quarter 2013 results at the end of July.

Aspen makes deals with Merck and GSK

Generics manufacturer Aspen Pharmacare Holdings (Aspen) is expanding its brand-name business, first signing a deal with Pharma giant Merck, and then offering to buy two brand-name heart medications from GlaxoSmithKline (GSK).

CFR pharma expands global ambitions with Adcock bid

Chile-based CFR Pharmaceuticals (CFR) has plans to become a global drugmaker. In its latest efforts it has made a US$1.3 billion cash-and-share offer for South Africa’s second-largest generics drugmaker Adcock Ingram (Adcock).

UK plans to cut drug prices by up to 20%

The UK’s Department of Health (DoH) has launched a consultation to strengthen the statutory pharmaceutical pricing scheme, which covers the prices the National Health Service (NHS) pays for brand-name drugs not covered by the voluntary Pharmaceutical Price Regulation Scheme (PPRS). The consultation is seeking views on a price cut on drug prices of between 10% and 20% to ensure the NHS continues to get good value for money.